BPGbio Publishes Pioneering AI-Guided Solid Tumor Study
Phase 1a/1b data in 97 patients with advanced solid tumors showed that intravenous BPM31510, a mitochondrial metabolic modulator, induced...
Phase 1a/1b data in 97 patients with advanced solid tumors showed that intravenous BPM31510, a mitochondrial metabolic modulator, induced...
Kalaris reported initial Phase 1a data for TH103 in treatment-naïve nAMD showing a mean 10-letter BCVA gain at Month...
Pemvidutide delivered statistically significant 48-week improvements on multiple non-invasive fibrosis markers in the Phase 2b IMPACT trial. Mean ELF...
vTv Therapeutics has submitted a Phase 2 protocol to the Department of Health, Abu Dhabi, for cadisegliatin in insulin-treated...
In a first-in-human study of 11 patients with recurrent malignant glioma, NXL-004 reported no drug-related serious adverse events or...
Actuate Therapeutics’ randomized Phase 2 trial of elraglusib added to gemcitabine/nab-paclitaxel in previously untreated metastatic pancreatic ductal adenocarcinoma has...
SAB Biotherapeutics has dosed the first patient in SAFEGUARD, a Phase 2b registrational study evaluating SAB-142, a fully human...
Actinogen has fully randomized 247 patients to its Phase 2b/3 XanaMIA study in mild to moderate Alzheimer’s disease, and...
In a randomized, placebo-controlled Phase 1 study of 16 healthy volunteers, intravenous OV350 met its primary safety, tolerability, and...
Revolution Medicines has randomized the first patient in RASolute 304, a global, open-label Phase 3 study testing daraxonrasib as...